Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs.

about

Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation

P2860

Q57093085-92BD2A0B-F9DF-4794-9D9F-78E6DEC19714

P2860

Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs.

Item

http://www.wikidata.org/entity/Q47619604

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Study Design and Evaluation of ...... rinology, and Metabolic Drugs.

@en

Study Design and Evaluation of ...... rinology, and Metabolic Drugs.

@nl

type

Item

label

Study Design and Evaluation of ...... rinology, and Metabolic Drugs.

@en

Study Design and Evaluation of ...... rinology, and Metabolic Drugs.

@nl

prefLabel

Study Design and Evaluation of ...... rinology, and Metabolic Drugs.

@en

Study Design and Evaluation of ...... rinology, and Metabolic Drugs.

@nl

P1476

Study Design and Evaluation of ...... rinology, and Metabolic Drugs.

@en

P2093

Enrica Alteri

http://www.w3.org/2001/XMLSchema#string

Giampiero Mazzaglia

http://www.w3.org/2001/XMLSchema#string

Heidi Janssen

http://www.w3.org/2001/XMLSchema#string

June Raine

http://www.w3.org/2001/XMLSchema#string

Peter Arlett

http://www.w3.org/2001/XMLSchema#string

Sabine M J Straus

http://www.w3.org/2001/XMLSchema#string

P2860

Misclassification of exposure is high when interview data on drug use are used as a proxy measure of chronic drug use during follow-up.

Advancing the field of pharmaceutical risk minimization through application of implementation science best practices.

Defining and classifying clinical indicators for quality improvement.

Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies.

Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses.

Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone.

A critical review of methods to evaluate the impact of FDA regulatory actions.

European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.

Impact of safety-related regulatory action on clinical practice: a systematic review.

Risk factors for hospital admissions associated with adverse drug events.

P2888

s40264-017-0604-4

P304

191-202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40264-017-0604-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniela de Fátima Teixeira da Silva

P577

2017-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29124666

http://www.w3.org/2001/XMLSchema#string

P932

5808048

http://www.w3.org/2001/XMLSchema#string

Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs.

about

P2860

P2860

Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932